Medical device company Boston Scientific plans to release its third quarter financial results on Oct. 22, according to a TREFIS report.
The company's financials have been in a slump for the past several years, but it reported growth in the second quarter of this year. New product launches are expected to sustain the uptick in growth in the company's third quarter.
Here is how the company's stock price breaks down by division:
• Interventional cardiology: 27.6 percent
• Pacemakers, defibrillators: 27.4 percent
• Endoscopy: 16.6 percent
• Peripheral interventions: 11.2 percent
• Urology and women's health: 7.3 percent
• Neuromodulation: 7 percent
• Electrophysiology: 2.2 percent
• Divested businesses: 0.7 percent
More articles on gastroenterology:
5 gastroenterologists making the news
Menthol spray show to improve ADR, reduce peristalsis
3 ways gastroenterologists can demonstrate value
The company's financials have been in a slump for the past several years, but it reported growth in the second quarter of this year. New product launches are expected to sustain the uptick in growth in the company's third quarter.
Here is how the company's stock price breaks down by division:
• Interventional cardiology: 27.6 percent
• Pacemakers, defibrillators: 27.4 percent
• Endoscopy: 16.6 percent
• Peripheral interventions: 11.2 percent
• Urology and women's health: 7.3 percent
• Neuromodulation: 7 percent
• Electrophysiology: 2.2 percent
• Divested businesses: 0.7 percent
More articles on gastroenterology:
5 gastroenterologists making the news
Menthol spray show to improve ADR, reduce peristalsis
3 ways gastroenterologists can demonstrate value